Article
miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
Pigment cell & melanoma research - 1 Jul 2015
Liu Shujing, Tetzlaff Michael T, Wang Tao, Yang Ruifeng, Xie Lin, Zhang Gao, Krepler Clemens, Xiao Min, Beqiri Marilda, Xu Wei, Karakousis Giorgos, Schuchter Lynn, Amaravadi Ravi K, Xu Weiting, Wei Zhi, Herlyn Meenhard, Yao Yuan, Zhang Litao, Wang Yingjie, Zhang Lin, Xu Xiaowei
Abstract excerpt
Resistance to BRAF inhibitors (BRAFi) is one of the major challenges for targeted therapies for BRAF-mutant melanomas. However, little is known about the role of microRNAs in conferring BRAFi resistance. Herein, we demonstrate that miR-200c expression is significantly reduced whereas miR-200c target genes including Bmi1, Zeb2, Tubb3, ABCG5, and MDR1 are significantly increased in melanomas that acquired BRAFi...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.